These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12957284)

  • 1. BRAF as a potential therapeutic target in melanoma and other malignancies.
    Tuveson DA; Weber BL; Herlyn M
    Cancer Cell; 2003 Aug; 4(2):95-8. PubMed ID: 12957284
    [No Abstract]   [Full Text] [Related]  

  • 2. Relief of inhibitory autophosphorylation activates RAF.
    Cancer Discov; 2013 Jul; 3(7):OF31. PubMed ID: 23847376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genome-based strategy uncovers frequent BRAF mutations in melanoma.
    Pollock PM; Meltzer PS
    Cancer Cell; 2002 Jul; 2(1):5-7. PubMed ID: 12150818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
    Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Brn-2 transcription factor links activated BRAF to melanoma proliferation.
    Goodall J; Wellbrock C; Dexter TJ; Roberts K; Marais R; Goding CR
    Mol Cell Biol; 2004 Apr; 24(7):2923-31. PubMed ID: 15024080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lucky draw in the gene raffle.
    Pollock PM; Meltzer PS
    Nature; 2002 Jun; 417(6892):906-7. PubMed ID: 12087387
    [No Abstract]   [Full Text] [Related]  

  • 8. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions.
    Smalley KS; Herlyn M
    J Invest Dermatol; 2004 Oct; 123(4):xvi-xvii. PubMed ID: 15373800
    [No Abstract]   [Full Text] [Related]  

  • 9. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
    Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
    Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raf proteins and cancer: B-Raf is identified as a mutational target.
    Mercer KE; Pritchard CA
    Biochim Biophys Acta; 2003 Jun; 1653(1):25-40. PubMed ID: 12781369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Raf activity by dimerization.
    Wei H; Zhou MM
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):156-7. PubMed ID: 20067555
    [No Abstract]   [Full Text] [Related]  

  • 14. The T1796A mutation of the BRAF gene is absent in Spitz nevi.
    Palmedo G; Hantschke M; Rütten A; Mentzel T; Hügel H; Flaig MJ; Yazdi AS; Sander CA; Kutzner H
    J Cutan Pathol; 2004 Mar; 31(3):266-70. PubMed ID: 14984580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
    Collisson EA; De A; Suzuki H; Gambhir SS; Kolodney MS
    Cancer Res; 2003 Sep; 63(18):5669-73. PubMed ID: 14522881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRAF R391W is a melanoma driver oncogene.
    Atefi M; Titz B; Tsoi J; Avramis E; Le A; Ng C; Lomova A; Lassen A; Friedman M; Chmielowski B; Ribas A; Graeber TG
    Sci Rep; 2016 Jun; 6():27454. PubMed ID: 27273450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
    Tsao H; Goel V; Wu H; Yang G; Haluska FG
    J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of exon 15 BRAF germline mutations in familial melanoma.
    Lang J; Boxer M; MacKie R
    Hum Mutat; 2003 Mar; 21(3):327-30. PubMed ID: 12619120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.